EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans

Victoire Cardot-Ruffino iD, Naima Bollenrucher, Luisa Delius, S Jennifer Wang, Lauren K Brais, Joshua Remland, C Elizabeth Keheler, Keri M Sullivan, Thomas A Abrams, Leah H Biller, Peter C Enzinger, Nadine J McCleary und 12 weitere

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2022-006589 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Victoire Cardot-Ruffino und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Neutropenia, Pancreatic Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, DFCI Hale Family Center for Pancreatic Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recombinant granulocyte colony-stimulating factor (G-CSF) is routinely administered for prophylaxis or treatment of chemotherapy-induced neutropenia. Chronic myelopoiesis and granulopoiesis in patients with cancer has been shown to induce immature monocytes and neutrophils that contribute to both systemic and local immunosuppression in the tumor microenvironment. The effect of recombinant G-CSF (pegfilgrastim or filgrastim) on the production of myeloid-derived suppressive cells is unknown. Here we examined patients with pancreatic cancer, a disease known to induce myeloid-derived suppressor cells (MDSCs), and for which pegfilgrastim is routinely administered concurrently with FOLFIRINOX but not with gemcitabine-based chemotherapy regimens.

Methods

Serial blood was collected from patients with pancreatic ductal adenocarcinoma newly starting on FOLFIRINOX or gemcitabine/n(ab)paclitaxel combination chemotherapy regimens. Neutrophil and monocyte frequencies were determined by flow cytometry from whole blood and peripheral blood mononuclear cell fractions. Serum cytokines were evaluated pretreatment and on-treatment. Patient serum was used in vitro to differentiate healthy donor monocytes to MDSCs as measured by downregulation of major histocompatibility complex II (HLA-DR) and the ability to suppress T-cell proliferation in vitro. C57BL/6 female mice with pancreatic tumors were treated with FOLFIRINOX with or without recombinant G-CSF to directly assess the role of G-CSF on induction of immunosuppressive neutrophils.

Results

Patients receiving FOLFIRINOX with pegfilgrastim had increased serum G-CSF that correlated with an induction of granulocytic MDSCs. This increase was not observed in patients receiving gemcitabine/n(ab)paclitaxel without pegfilgrastim. Interleukin-18 also significantly increased in serum on FOLFIRINOX treatment. Patient serum could induce MDSCs as determined by in vitro functional assays, and this suppressive effect increased with on-treatment serum. Induction of MDSCs in vitro could be recapitulated by addition of recombinant G-CSF to healthy serum, indicating that G-CSF is sufficient for MDSC differentiation. In mice, neutrophils isolated from spleen of G-CSF-treated mice were significantly more capable of suppressing T-cell proliferation.

Conclusions

Pegfilgrastim use contributes to immune suppression in both humans and mice with pancreatic cancer. These results suggest that use of recombinant G-CSF as supportive care, while critically important for mitigating neutropenia, may complicate efforts to induce antitumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsNeutropeniaPancreatic NeoplasmsAnimalsFemaleHumansMiceGemcitabineGranulocyte Colony-Stimulating FactorImmunosuppression TherapyLeukocytes, MononuclearMice, Inbred C57BLPaclitaxelRecombinant ProteinsTumor MicroenvironmentLeucovorinFluorouracilIrinotecanOxaliplatin

Stichwörter der Autor:innen

cytokinesgastrointestinal neoplasmsimmunotherapymyeloid-derived suppressor cellsneutrophil infiltration

Substanzen

GemcitabineGranulocyte Colony-Stimulating FactorPaclitaxelRecombinant ProteinsfolfirinoxLeucovorinFluorouracilIrinotecanOxaliplatin

Autor:innen und Institutionen

  • Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Immunology, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA stephanie_dougan@dfci.harvard.edu.

ORCID-Profile: Victoire Cardot-Ruffino, Douglas A Rubinson, Stephanie K Dougan

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • DFCI Hale Family Center for Pancreatic Cancer Research
  • COHRP Fund for Pancreatic Cancer Research
  • NIH
  • Ludwig Center at Harvard
  • Break Through Cancer
  • Pancreatic Cancer Action Network and the Francois Wallace Monahan Fund in loving memory of Michael Insel

Zitieren

APA

Cardot-Ruffino, V., Bollenrucher, N., Delius, L., Wang, S. J., Brais, L. K., Remland, J., Keheler, C. E., Sullivan, K. M., Abrams, T. A., Biller, L. H., Enzinger, P. C., McCleary, N. J., Patel, A. K., Rubinson, D. A., Schlechter, B., Slater, S., Yurgelun, M. B., Cleary, J. M., Perez, K., …, & Dougan, S. K. (2023). G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006589

Vancouver

Cardot-Ruffino V, Bollenrucher N, Delius L, Wang SJ, Brais LK, Remland J, et al. G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-006589

BibTeX
@article{CardotRuffino2023,
  author = {Cardot-Ruffino, Victoire and Bollenrucher, Naima and Delius, Luisa and Wang, S Jennifer and Brais, Lauren K and Remland, Joshua and Keheler, C Elizabeth and Sullivan, Keri M and Abrams, Thomas A and Biller, Leah H and Enzinger, Peter C and McCleary, Nadine J and Patel, Anuj K and Rubinson, Douglas A and Schlechter, Benjamin and Slater, Sarah and Yurgelun, Matthew B and Cleary, James M and Perez, Kimberly and Dougan, Michael and Ng, Kimmie and Wolpin, Brian M and Singh, Harshabad and Dougan, Stephanie K},
  title = {G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2022-006589}
}
Kostenlos starten →